Kamada Ltd.

KMDA Healthcare Drug Manufacturers Specialty & Generic

Kamada Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $180.5 million, up 12.1% from fiscal 2024. In the quarter to June 2026, revenue grew 22.7%, EPS grew 23.1%, free cash flow grew 165.7% and total debt fell 38.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

7.77 0.06 −0.77%
Market cap
$451.7M
P/E
20.4×
Fwd P/E
0.0×
Dividend yield
5.41%
F-score
7/9
Altman Z
3.33
Beneish M
−2.35
Dividend safety
50/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

7.86% 7.64% 7.97% 8.40%
Piotroski F-Score
7 7 7 7
ROA
5.61% 5.38% 5.37% 5.92%
ROIC
8.51% 8.06% 8.06% 8.47%
Return on Tangible Assets
11.17% 10.80% 11.26% 11.49%
Average Days of Receivables
73.77 66.06 81.67 80.98
Free Cash Flow per Share
0.31 0.27 0.28 0.45
Free Cash Flow
18.34 15.65 16.36 26.32
Capital Expenditures
(9.99) (9.84) (9.35) (9.44)
Other line items
Cash ROIC
5.27% 4.42% 4.77% 7.61%
Accounts Receivable Turnover
6.22 6.04 4.87 4.93
Accounts Payable Turnover
3.44 2.86 2.35 3.05
Inventory Turnover
1.25 1.27 1.31 1.34
Average Days of Payables
127.41 124.00 160.01 130.78
Days of Inventory on Hand
317.10 297.97 291.69 279.29
Tax Rate
(0.04) (0.14) (0.08) (0.17)
Research and Development Expense of Revenue
7.31% 7.20% 6.02% 5.17%
Selling, General and Administrative Expense of Revenue
20.22% 20.60% 21.17% 21.15%
Share Based Compensation of Revenue
0.32% 0.47% 0.81% 1.09%
Interest Coverage
34.96 30.36 29.52 26.79
Operating CF/Net income
1.39 1.26 1.26 1.61
Depreciation/Fixed assets
0.40 0.36 0.37 0.35
Capex/Depreciation
(0.66) (0.66) (0.62) (0.62)
Revenue per Share
2.97 3.13 3.08 3.31
Operating CF per Share
0.48 0.44 0.44 0.62
Capex per Share
(0.17) (0.17) (0.16) (0.16)
Capex to Sales
0.06 0.05 0.05 0.05

Fold the line items

Columns are period end dates